Determine the necessary mass, volume, or concentration for preparing a solution.
Saralasin ([Sar1,Ala8] Angiotensin II) TFA is an octapeptide analog of angiotensin II. Saralasin TFA is a competitive angiotensin II receptor antagonist with a K i value of 0.32 nM for 74% of the binding sites, and has partial agonist activity as well. Sa
Appearance:Solid
IC50& Target:Ki: 0.32 nM (Angiotensin II receptor)
In Vitro:Saralasin TFA (1 nM, 48 or 72 h) inhibits cell growth in 3T3 and SV3T3 cells. Saralasin TFA (5 μM, 2h) restores I to, fast (Fast-Inactivating Transient Outward K+ Current in Mouse Ventricle) and I K, slow (Slow-Inactivating Transient Outward K+ Curre
In Vivo:Saralasin TFA (intravenous injection, 5-50 μg/kg, a single dose) ameliorates the oxidative stress and tissue injury in cerulein-induced pancreatitis. Saralasin TFA (subcutaneous injection, 10 and 30mg/kg, a single dose) increases serum renin activit
Biological Activity:Saralasin ([Sar1,Ala8] Angiotensin II) TFA is an octapeptide analog of angiotensin II. Saralasin TFA is a competitive angiotensin II receptor antagonist with a K i value of 0.32 nM for 74% of the binding sites, and has partial agonist activity as well. Sa
| Solubilità | H2O : 100 mg/mL (97.46 mM; Need ultrasonic) DMSO : 50 mg/mL (48.73 mM; Need ultrasonic) |
|---|